Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening
Open Access
- 31 May 2009
- journal article
- research article
- Published by Elsevier in Journal of Hepatology
- Vol. 50 (5) , 990-998
- https://doi.org/10.1016/j.jhep.2008.12.022
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Surveillance of cirrhosis for hepatocellular carcinoma: a cost–utility analysisBritish Journal of Cancer, 2008
- Cost‐effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstancesJournal of Gastroenterology and Hepatology, 2007
- Hepatocellular carcinoma in Sydney South West: late symptomatic presentation and poor outcome for mostInternal Medicine Journal, 2007
- Lamivudine treatment in patients with chronic hepatitis B and cirrhosisExpert Opinion on Pharmacotherapy, 2006
- Hepatocellular Carcinoma and Hepatitis B VirusSeminars in Liver Disease, 2006
- Treatment of chronic hepatitis B: Who to treat, what to use, and for how long?Clinical Gastroenterology and Hepatology, 2004
- Antiviral therapy in patients with chronic hepatitis B and cirrhosisGastroenterology Clinics of North America, 2004
- Randomized controlled trial of screening for hepatocellular carcinomaZeitschrift für Krebsforschung und Klinische Onkologie, 2004
- Cancer in NSW: incidence and mortality 1997New South Wales Public Health Bulletin, 2001
- Cost-Effectiveness Analysis and the Consistency of Decision MakingPharmacoEconomics, 2001